LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
Conference call and webcast on
Conference Call and Webcast Event
The Company will host a conference call and webcast tomorrow,
About LENZ Therapeutics
LENZ Therapeutics is a late clinical-stage biopharmaceutical company focused on developing the first aceclidine-based eye drop to improve vision in patients diagnosed with presbyopia. LENZ’s product candidates, LNZ100 and LNZ101, are preservative-free, single-use, once-daily eye drops containing aceclidine and aceclidine plus brimonidine, respectively. LNZ100 and LNZ101 are under clinical evaluation in the registration-enabling Phase 3 CLARITY trials as potential therapies for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding the timing, progress and results of our clinical trials for our current product candidates, including statements regarding the reporting of data from our current trials; our plans relating to the clinical development of our product candidates; the size of the market opportunity for our product candidates; our plans relating to commercializing our product candidates, if approved; and the beneficial characteristics of our product candidates. These statements are based on numerous assumptions concerning the development of LENZ’s products and target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled “Risk Factors” in the final 424B3 proxy statement/prospectus filed with the
View source version on businesswire.com: https://www.businesswire.com/news/home/20240402093553/en/
LENZ Therapeutics
IR@LENZ-Tx.com
Stern Investor Relations, Inc.
janhavi.mohite@sternir.com
Source: